
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Xenetic Biosciences Inc (XBIO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XBIO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $40
1 Year Target Price $40
0 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.57% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.41M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 1 | Beta 2.33 | 52 Weeks Range 2.20 - 5.27 | Updated Date 08/15/2025 |
52 Weeks Range 2.20 - 5.27 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -126.03% | Operating Margin (TTM) -122.8% |
Management Effectiveness
Return on Assets (TTM) -28.37% | Return on Equity (TTM) -51.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -367525 | Price to Sales(TTM) 1.8 |
Enterprise Value -367525 | Price to Sales(TTM) 1.8 | ||
Enterprise Value to Revenue 0.19 | Enterprise Value to EBITDA 1.03 | Shares Outstanding 1542140 | Shares Floating 1182805 |
Shares Outstanding 1542140 | Shares Floating 1182805 | ||
Percent Insiders 19.05 | Percent Institutions 4.8 |
Upturn AI SWOT
Xenetic Biosciences Inc

Company Overview
History and Background
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapeutics. Founded in 2003, it has focused on polymer-based drug delivery and has gone through multiple strategic shifts. Key milestones include development programs utilizing PolyXen technology.
Core Business Areas
- Oncology: Focused on developing therapies for cancer, particularly targeting solid tumors. This segment utilizes Xenetic's PolyXen technology.
- COVID-19 vaccine: Developing novel vaccine therapies for infectious diseases, including a potential COVID-19 vaccine.
Leadership and Structure
The leadership team includes a Chief Executive Officer (CEO) and a board of directors. The organizational structure typically includes departments for research and development, clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- ErepoXen: ErepoXen, a long-acting form of erythropoietin (EPO) for treating anemia. Competitors: Amgen (AMGN) with Epogen/Aranesp, Johnson & Johnson (JNJ) with Procrit/Eprex. Market share data is not publicly available.
- OncoHist: OncoHist, a potential treatment for cancer. Market share data is not publicly available at the development stage. Competitors depend on the specific cancer target if approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. Innovation and patent protection are crucial for success.
Positioning
Xenetic is a smaller player in the biopharmaceutical industry, focusing on niche therapeutic areas. Its competitive advantage lies in its PolyXen technology, which aims to improve drug delivery and efficacy.
Total Addressable Market (TAM)
The total addressable market (TAM) for oncology therapeutics is estimated to be in the hundreds of billions of dollars globally. Xenetic Biosciences, Inc. is attempting to penetrate a very small section of this market with novel treatments.
Upturn SWOT Analysis
Strengths
- Proprietary PolyXen technology
- Potential for improved drug delivery
- Pipeline of therapeutic candidates
Weaknesses
- Limited financial resources
- Small market capitalization
- Dependence on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Expanding applications of PolyXen technology
Threats
- Regulatory hurdles
- Competition from established players
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- AMGN
- JNJ
- VTRS
Competitive Landscape
Xenetic faces significant competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its PolyXen technology offers a potential competitive edge if proven effective.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's development stage and lack of product revenue.
Future Projections: Future projections are speculative and depend on the success of clinical trials and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives likely include progressing clinical trials for its lead therapeutic candidates and securing funding for operations.
Summary
Xenetic Biosciences is a development-stage biopharmaceutical company with limited revenue and high risk. Its PolyXen technology offers potential, but the company depends on clinical trial success and funding. It faces significant competition and regulatory hurdles. Success depends on the ability to advance its pipeline and secure partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share estimations are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenetic Biosciences Inc
Exchange NASDAQ | Headquaters Framingham, MA, United States | ||
IPO Launch date 2014-06-30 | CFO, COO, Interim CEO & Corporate Secretary Mr. James F. Parslow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.xeneticbio.com |
Full time employees 2 | Website https://www.xeneticbio.com |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.